News
-
-
PRESS RELEASE
EQS-Adhoc: Bayer Aktiengesellschaft: Bayer’s Asundexian Met Primary Efficacy and Safety Endpoints in Landmark Phase III OCEANIC-STROKE Study in Secondary Stroke Prevention
Bayer announces positive results from Phase III OCEANIC-STROKE study, showing asundexian reduces ischemic stroke risk with antiplatelet therapy -
-
PRESS RELEASE
EQS-Adhoc: Bayer Aktiengesellschaft: Bayer upgrades currency-adjusted sales and earnings guidance for 2025 and establishes additional provisions for litigation in the United States
Bayer upgrades currency-adjusted sales and earnings guidance for 2025, establishes provisions for US litigation, and expects to significantly contain US glyphosate claims by end of 2026 -
-
-